🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New meta-analysis highlights the limited data on cervicogenic #headache prevalence & frequency. Clinic-based studies suggest a 3.1% relative frequency, with women most affected. More research is needed to refine diagnosis & classification Cephalalgia rb.gy/1e6qqt

Almost 40 years ago, the discovery of the vasoactive neuropeptide calcitonin gene-related peptide (CGRP) ushered in a new era in migraine treatment. A new Therapeutics Review explores the current role of CGRP and future perspectives. Read this & more 👉 hubs.li/Q03cTB240

Great to lecture at #AAN2025 on neuromodulation and surgical treatment for headache as part of the interventional management workshop. Grateful to join top #HeadacheSpecialist colleagues for a successful and high-impact session! #HeadacheMedicine #Neurology #AANAM

Honored to co-author editorial on non-opioid options for chronic pain. With approval of suzetrigine (NaV1.8 inhibitor), we highlight the urgent need for safer, evidence-based, and multimodal approaches to pain care #ChronicPain #NonOpioid #PainManagement👇 shorturl.at/uo2Nc

🧠 Ready to present your research on a global stage? Submit your abstract to IHC 2025 and join the leading global programme in headache medicine. 📅 Deadline: 5 May 2025 – 23:59 (Brasília time) 🔗 Submit now: ihc2025.org

😴💥 Snore. Pause. Headache? About 54 million Americans are living with obstructive sleep apnea, but nearly 80% remain undiagnosed. During Sleep Apnea Education Week by Alliance of Sleep Apnea Partners (ASAP), learn more about the signs, risks, and why early diagnosis matters. 🔗 apneapartners.org/saew

Proud to be part of this work with my colleagues! We present new evidence-based guidelines for #migraine treatment, developed by the Italian Society for the Study of Headache and the International Headache Society #Headache #Neurology #Pain shorturl.at/0OMZL

SISC-IHS guideline for pharmacological treatment of #migraine is now published Cephalalgia Simona Sacco @Schwedtt Messoud Ashina Sait Ashina Jr Wei Wu, MD @Faradoost @ninariggins doi.org/10.1177/033310…

📢 New Migraine Treatment Guidelines Out Now! 🧠💊 The International Headache Society and Italian Society for the Study of Headache have published evidence-based guidelines for the pharmacological treatment of migraine, covering both acute and preventive therapies. Built on

📢 New Migraine Treatment Guidelines Out Now! 🧠💊 The International Headache Society and Italian Society for the Study of Headache have published evidence-based guidelines for the pharmacological treatment of migraine, covering both acute and preventive therapies. Built on

🚀 Advancing Migraine Care: New Guidelines Released! The International Headache Society and Italian Society for the Study of Headache present the latest evidence-based guidelines for acute and preventive migraine treatment. Clear, rigorous, and practical—these guidelines are a

🚀 Advancing Migraine Care: New Guidelines Released! The International Headache Society and Italian Society for the Study of Headache present the latest evidence-based guidelines for acute and preventive migraine treatment. Clear, rigorous, and practical—these guidelines are a

🧠✨ New Evidence-Based Guidelines for Migraine Treatment! The International Headache Society and Italian Society for the Study of Headache have released updated guidelines for the pharmacological management of migraine, covering both acute attacks and preventive strategies. A

New study: IV infusion of substance P induced headache and arterial dilation in healthy adults. 71% reported #headache vs 10% with placebo. Findings support a role for substance P in headache pathogenesis #migraine #neurology #SubstanceP Cephalalgia shorturl.at/6l9vv

Al-Khazali et al. reported that individuals with persistent post-traumatic headache (PTH) exhibit disability and headache profiles comparable to those with chronic migraine, emphasizing the necessity for targeted management strategies akin to chronic migraine care.

June is Migraine Awareness Month Migraine is a debilitating neurological disorder that affects over 1 billion people worldwide, with 14–15% of the global population experiencing it. Women are two to three times more likely to be affected, often due to hormonal influences. This

First US population-based survey on CGRP mAb use in migraine now out! Only 5% had ever used them. Top predictors: acute med use, triptan contraindications. Real-world insights to guide personalized care 👉 shorturl.at/uozbx #Migraine #CGRP #Headache Cephalalgia

June is #MigraineAwarenessMonth! Do you know there are clear criteria for diagnosing migraine? The ICHD‑3 criteria, developed by the International Headache Society’s Classification Committee, give clinicians a clear guide for diagnosing headache disorders. Swipe the

🧪 New biomarker insights in migraine! A cross-sectional study of over 750 adults reveals: 🔹 Serum GFAP levels are modestly but significantly higher (+6.8%) in people with migraine vs. healthy controls. 🔹 Serum NfL levels? No difference found. 🔹 Results were independent of

📢 New publication alert! “Intact white matter in adults with migraine: A REFORM MRI study” 🧠 Using advanced diffusion tensor imaging (DTI), this large case-control study of nearly 300 migraine patients found no significant differences in white matter integrity compared to